|
Shopping Cart
Your Cart is currently empty.
Member Login
Letters
Autoimmune Hepatitis with anti SLA antibodiesPrice: €10,00 |
|
| Autoimmune hepatitis (AIH) is a chronic progressive
liver disease characterized by female predominance,
hypergammaglobulinemia, specific autoantibodies, an
association with HLA DR3 & DR4 and a favourable
response to immunosuppressive treatment. The diagnosis
of AIH includes a combination of clinical, laboratory and
histological features (1).
Three subtypes of AIH have been proposed based on
the different immunomarkers. Type I AIH, the most common
form of the disease is associated with antinuclear
(ANA) and anti smooth muscle (SMA) antibodies,
affects all age group and is associated with HLA DR3
and DR4 (2). Type 2 AIH characterized by the presence
of anti-liver kidney microsomal-1(LKM1) antibodies, is
associated with HLA DRB1 and has a poorer outcome
(2,3). Type 3 AIH defined by the presence of antisoluble
liver antigen/liver pancreas antibodies (anti-
SLA/LP), is a rare condition, representing less than 10%
of all AIH (4-6). [Product Details...] |
|
Endoscopic and ultrasonographic diagnosis of intramural small bowel hematoma apparently caused by warfarinPrice: €10,00 |
|
| Nontraumatic intramural hematoma in the small
bowel is uncommon, but has been reported to occur in
the jejunum, ileum and duodenum in descending order of
frequency (1). For diagnosis of this condition,
endoscopy, computed tomography or ultrasonography
are usually sufficient (1,2). Here we describe the endoscopic
and ultrasonographic findings of a patient who
had intramural small bowel hematoma apparently caused
by warfarin.
A 66-year-old woman presented at our hospital’s
emergency department with abdominal pain, fever,
anorexia and melena. Her past medical history was
notable for prosthetic mitral valve, hypertension, coronary
artery disease, facial paralysis and diabetes mellitus.
Her current medications included warfarin
(7.5 mg/day), aspirin, acarbose, gliclazide, spironolactone
and beta blockers. Physical examination revealed
tenderness and a palpable mass in the epigastric region.
Digital rectal examination confirmed melena. [Product Details...] |
|
Ileocolonic involvement of follicular small cell lymphoma : A Rare EntityPrice: €10,00 |
|
| Follicular lymphoma (FL) is the most common of the
indolent lymphomas. On the other hand, FLs occur
seldom in the gastrointestinal tract (GIT), representing
only 1-3% of all GIT B-cell non-Hodgkin lymphomas.
The most frequent site of involvement is the small intestine,
particularly the duodenum and terminal ileum,
followed by colon (1). In the literature, only one case of
the terminal ileum and colonic involvement of follicular
lymphoma has been reported (2). Herein, we report a
second case of terminal ileum and colon involvement by
a follicular small cell lymphoma. [Product Details...] |
|
Pegylated interferon associated lichen planus at the injection sitePrice: €10,00 |
|
| Pegylated interferon alpha-2b (PEG-IFN) is a formulation
of recombinant human interferon conjugated with
polyethylene glycol. Compared with standard interferon,
pegylated interferon has a longer half-life and superior
antiviral efficacy in the treatment of hepatitis C. So it has
become the standard therapy with ribavirin for the treatment
of chronic hepatitis C (CHC) (1). One of the side
effects of pegylated interferon is localized inflammatory
skin lesions such as eczematous reactions, cutaneous
necrosis and vitiligo at the injection site. Herein we
report the first case of lichen planus (LP) at the injection
site due to pegylated interferon and ribavirin combination
therapy. [Product Details...] |
|
Reversible sudden sensorineural hearing loss during chronic hepatitis C treatment with pegylated interferon/ribavirin : letter to editorPrice: €10,00 |
|
| Combination of pegylated interferon alpha (PegIFNa)
plus ribavirin is currently the standard therapy for
patients with chronic hepatitis C (CHC). Sudden hearing
loss (SHL) is a rare complication of CHC treatment that
is not well documented. We report a case of a 42-yearold
Greek man with CHC (genotype 1b) who developed
right-sided hearing loss 46 weeks after the initiation of
therapy with PegIFNa-2a subcutaneously, at a dose of
180 μg/week, and ribavirin orally, at a dose of
1200 mg/day, for a scheduled period of 48 weeks. Before
treatment his clinical examination (including neurologic
assessment) was normal and there was no history of previous
disease or consumption of any drug or alcohol.
Serum levels of glucose, urea, creatinine, electrolytes,
lipids, alkaline phosphatase, gamma glutamyltransferase,
bilirubin, albumin, ferritin and blood cell count
were normal. [Product Details...] |
|
- «« Start
- « Prev
- 1
- Next »
- End »»
Acta gastroenterologica is abstracted/indexed in Current Contents, Excerpta Medica, Index medicus, ISI.
Published by © Universa Press, Wetteren, Belgium. All rights reserved.
Published by © Universa Press, Wetteren, Belgium. All rights reserved.